Estimated longevity benefit: +3.3 years. Evidence score: 61/100.
The combination of rapamycin and acarbose simultaneously inhibits the mTOR growth pathway and blunts post-meal glucose-insulin spikes. This synergistic approach targets multiple pillars of aging and has achieved the most significant lifespan extension ever documented in gold-standard animal studies.